MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session

Reuters

06-21

<a href="https://laohu8.com/S/MTVA">MetaVia Inc</a>. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session

Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545486451"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545486451\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545486451?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-21 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545486451","market":"us","top_or_hot":-1,"title":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-21 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MTVA","symbol_name":"MetaVia Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250621:nNDL9HFWGp:1","article_id":"2545486451","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545486451","pubTimestamp":1750510819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session. Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis . The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes online.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MTVA":"MetaVia Inc","BK4139":"生物科技"},"translate_title":"MetaVia Inc.在ADA科学会议上宣布DA-1241与Efruxifermin联合治疗MASH的有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n    \n\n        Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}